Choose Your Country or Region

LY294002

Name: LY294002
Brand: Selleck Chemicals
SKU: S1105
Rating: 5 (1417 reviews)

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1417 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Targets

CK2 ^[5] (Cell-free assay)	p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	DNA-PK ^[6] (Cell-free)
98 nM	0.5 μM	0.57 μM	0.97 μM	1.4 μM

In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1^[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). ^[2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Sf9 cells	MU\GeY5kfGmxbjDhd5NigQ>?			MVvJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u	MojGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUizOVEoRjFyOUm4N\|UyRC:jPh?=
HeLa cells	NVmweGk2SmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?=			MkPNRolv\GmwZzDh[oZqdmm2eTDmc5IhWEl\|LXvpcoF{\SCrc3;sZZRm\CCocn;tJGhmVGFiY3XscJMtKEurPU[g{txO	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O\|AoRjF3NkW4PFcxRC:jPh?=
HeLa cells	M4\sSmZ2dmO2aX;uJIF{e2G7			MWfJcohq[mm2aX;uJI9nKG2WT2KgdJJwfGWrbjDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFnDOVA:Oi53IN88UU4>	NWXtUYZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
HeLa (human carcinoma) cells.	M17UXGZ2dmO2aX;uJIF{e2G7			NUTiVYpqUW5idnn0do8hcW6qaXLpeIlwdiCxZjDEUmEu\GWyZX7k[Y51KHC{b4TlbY4hc2mwYYPlLGRPSS2SSzmg[pJwdSCKZVzhJEhpfW2jbjDjZZJkcW6xbXGpJINmdGy\|LDDJR\|UxRTFwNDFOwG0v	NI\OXYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[1PFg4OCd-MUW2OVg5PzB:L3G+
human PC3 cells	MkTGVJJwdGmoZYLheIlwdiCjc4PhfS=>	MmHoNlUh\|ryP	MYCxNlAhcA>?	NG\WSWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDheEAzPSC3TTDh[pRmeiBzMkCgbJJ{KGK7IF3UWEBie3OjeTDy[YxifGm4ZTD0c{BFVVOR	NYG0SFY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
human BJ cells	Ml3hSpVv[3Srb36gZZN{[Xl?	NVz1Tm1EOjVizszN	M4LiflIhcA>?	NWH0N3g2SWO2aY\heIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPEBqdiCSRFfGMZN1cW23bHH0[YQhe2W{dX2gd5Rien[nZDDoeY1idiCESjDj[YxteyCjdDCyOUB2VSC2cnXheIVlKDJiaILzJIJm\m:{ZTDQSGdHKGOqYXzs[Y5o\SCkeTDpcY12dm:kbH;0eIlv\w>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd4N{C4OUc,OTZ5NkewPFU9N2F-
human BJ cells	M4OyPGZ2dmO2aX;uJIF{e2G7	NYrxN2xZOjVizszN	NVjVVWlDOiCq	MVXJcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?=	NIPKblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke2O\|A5PSd-MU[3OlcxQDV:L3G+
mouse mast cells	MoL1SpVv[3Srb36gZZN{[Xl?	NF7yTY0zOCEQvF2=		MYLJcohq[mm2aX;uJI9nKFOFRj3pcoR2[2WmIGDLRk9Cc3RicHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKG2jc4SgZ4VtdHNiYYSgNlAh\|ryP	MlrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O\|QzRC:jPh?=
THP1 cells	MWLGeY5kfGmxbjDhd5NigQ>?			MmrpTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgZ4hmdW:2YYjpd{Bw\iCWSGCxJINmdGy\|LDDJR\|UxRTN5IN88UU4>	NUPiWGkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
mouse Raw264 macrophage	MoPMSpVv[3Srb36gZZN{[Xl?			NIjrTIJKdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W\|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v	NVzoZo9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
THP1 cells	NH31O2FHfW6ldHnvckBie3OjeR?=			NGXWSVlKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvPjVizszNMi=>	Mn22QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O\|QzRC:jPh?=
THP1 cells	NFP0S3JHfW6ldHnvckBie3OjeR?=			MoXHTY5pcWKrdHnvckBw\iCVQ1[xMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlAyKM7:TT6=	NGrFVVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
human A375 cells	NWDYOIl4WHKxbHnm[ZJifGmxbjDhd5NigQ>?		NUn6cllvPDZiaB?=	MkjRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDM{e1JINmdGy\|IHHmeIVzKDR4IHjyd{whUUN3ME24MlQh\|ryPLh?=	NXXFS4pSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOFkzPDhpPkG3NFQ6OjR6PD;hQi=>
HeLa cells	NXPZSmYyTnWwY4Tpc44h[XO\|YYm=			M1jwNGlvcGmkaYTpc44hd2ZiQWitO\|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF\|NUK0PEc,OTdzM{WyOFg9N2F-
human SW480 cells	MmDkSpVv[3Srb36gZZN{[Xl?	MYOyNEDPxE1?	MnLRNlQhcA>?	MnXVSIVkemWjc3WgbY4he3W{dnn2bY4h\XiycnXzd4lwdiCrbjDoeY1idiCVV{S4NEBk\WyuczDheEAzOCC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	NXTJ[JQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0O\|I6PjJpPkG3OFczQTZ{PD;hQi=>
human A375 cells	M4rae3Bzd2yrZnXyZZRqd25iYYPzZZk>			NIjKdldKdmirYnn0bY9vKG:oIIPldpVuNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDv[kBpfW2jbjDBN\|c2KGOnbHzzMEBKSzVyPUiuOEDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMUezPUc,OTd4MEG3N\|k9N2F-
human A2780 cells	NFHhfnhCeG:ydH;zbZMh[XO\|YYm=	NIG5c\|kzKM7:TR?=	NE\4cGEyOiCq	M4nXe2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gZ4l{eGyjdHnuMZJme2m\|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDa4SgcIV3\WxiYYSgNkB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqey5?	M1jxWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki0NFE5Lz5zN{[4OFAyQDxxYU6=
human H4 cells	NFTaNFlHfW6ldHnvckBie3OjeR?=		NVHmN4tpOiCq	NHflbGlF\WO{ZXHz[UBqdiCIWW\FMXJHWCtidnXzbYNt\SCrboTlcpNqfHlicHXyJINmdGxiaX6gbJVu[W5iSESgZ4VtdHNiYX\0[ZIhOiCqcoOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	NH7UUYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECyOFU5PCd-MUiwNlQ2QDR:L3G+
Sf9 cells	MXrGeY5kfGmxbjDhd5NigQ>?			NXiwR4NMUW6qaXLpeIlwdiCxZjDDT\|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD14Lkmg{txONg>?	M3noN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{KxO\|E3Lz5zOEOyNVcyPjxxYU6=
rat RBL2H3 cells	M3;lWmZ2dmO2aX;uJIF{e2G7			MYXJcohq[mm2aX;uJI9nKEF{M{G4O{1qdmS3Y3XkJIRm\3KjboXsZZRqd25iaX6gdoF1KFKETELIN{Bk\Wyucx?=	M2f3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{K4O\|E3Lz5zOEOyPFcyPjxxYU6=
human U87MG cells	NWr5foljTnWwY4Tpc44h[XO\|YYm=			NVP5ZpJzUW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN2NU[wPUc,OTh\|NEW2NFk9N2F-
human H460 cells	NUn5WnZ{TnWwY4Tpc44h[XO\|YYm=	M4TjXFMxKM7:TR?=		M{jxUGlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJPDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IFHreEBxcG:\|cHjvdplt[XSrb36gZZQhW2W{IES3N{B2eCC2bzCzNEB2VQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVyMU[wNUc,OTh3MEG2NFE9N2F-
human U251HRE cells	NUjaXHI3TnWwY4Tpc44h[XO\|YYm=			MYLJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OUiURTDj[YxteyCkeTDj[YxtKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk>	MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human 184B5 cells	NEjjcWdEgXSxdH;4bYPDqGG\|c3H5			MkLnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVg1SjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTN7LkO3JO69VS5?	NH74fFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-468 cells	NI\wcINEgXSxdH;4bYPDqGG\|c3H5			MnvsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDifUBUWkJiYYPzZZktKEmFNUC9NVAvPCEQvF2u	M3jxTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells	M{G2TmN6fG:2b4jpZ:Kh[XO\|YYm=			MkHzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW\|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO\|YYmsJGdKPTB;OD6yJO69VS5?	M1nq[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-231 cells	M{\lXWN6fG:2b4jpZ:Kh[XO\|YYm=			MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlcyKM7:TT6=	NXXmO2RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells	MmT5R5l1d3SxeHnjxsBie3OjeR?=			NUjoR3JUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4>	NWjmNmRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells	NH\1cIxEgXSxdH;4bYPDqGG\|c3H5			NHHxe41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME20MlM2KM7:TT6=	NX3ue3R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells	MmPOR5l1d3SxeHnjxsBie3OjeR?=			Mn\NR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW\|ZX7j[UBw\iB{MDFOwG0h[2iub4LvdZVqdmViYomgV3JDKGG\|c3H5MEBIUT1\|LkOyJO69VS5?	NILPWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells	M2PHcmN6fG:2b4jpZ:Kh[XO\|YYm=			NUOySG1JS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKRTNwMU[g{txONg>?	M2Gyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells	M2SwVmN6fG:2b4jpZ:Kh[XO\|YYm=			NU\RdGRZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyOCC3TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oy5yODFOwG0v	NILiSXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells	M1G3dGN6fG:2b4jpZ:Kh[XO\|YYm=			NUTLZpF6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAzOCEQvF2gZ4htd3KxcYXpcoUh[nliU2LCJIF{e2G7LDDHTVUxRTJwNkOg{txONg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
Sf21 cells	NWXSVYltTnWwY4Tpc44h[XO\|YYm=			NGXrUHpKdmirYnn0bY9vKG:oIH3veZNmKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OD1yLkWg{txONg>?	NFPHVGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFI3QSd-MUm3OFgzPjl:L3G+
Sf9 cells	MoTa[ox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6			NFLveVJKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N\|E9N2F-
Sf9 cells	NH3ofnJHdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl?			M1O0NWlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR\|UxRTBwNUWg{txONg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N\|E9N2F-
human IGROV1 cells	NXqwNWxQTnWwY4Tpc44h[XO\|YYm=		NFjuTIszPCCq	MkfaR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDC1JIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl?	MlXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells	Mo[ySpVv[3Srb36gZZN{[Xl?		MX2yOEBp	M1zvS2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgNUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK\|IHL5JIZtd3diY4n0c41mfHK7	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells	M{PkcGZ2dmO2aX;uJIF{e2G7		M4DBfVI1NzR6IHi=	MXvJcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCleXPsbY4hTDFibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	Ml31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells	MVfGeY5kfGmxbjDhd5NigQ>?		MlXHNlQwPDhiaB?=	NVL6c5NrUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQVvUJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NGX4clM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human HCT116 cells	MXPDfZRwfG:6aXRCpIF{e2G7		NEHFTWk4OiCq	MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME21Ok4xOSEQvF2u	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
human KB cells	MnO2R5l1d3SxeHnjxsBie3OjeR?=		NEDkd3Y4OiCq	MmHDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12ND63OkDPxE1w	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
HUVEC	M1HL[mZ2dmO2aX;uJIF{e2G7	NUezVYtPOTBvMkWg{txO	MmfaN\|AhdWmw	NYDuXFNpUW6qaXLpeIlwdiCxZjDUUmZidHCqYT3zeIlufWyjdHXkJIh2dWGwIFnDRW0uOSCycn;tc5RmeiCjY4Tpeol1gSCneIDy[ZN{\WRiaX6gTHVXTUNiYYPz[ZN{\WRiYYOgZoV1[S2pYXzhZ5Rwe2mmYYPlJIFkfGm4aYT5JIF1KDFyIITvJFI2KHWPIIDy[ZRz\WG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJHRPTmGucHjhJINp[WyuZX7n[UBu\WG\|dYLl[EBi\nSncjC1JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	M1rFfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK2OFExLz5{MkCyOlQyODxxYU6=
HUVEC	NVKyUIwzTnWwY4Tpc44h[XO\|YYm=	M1HlXVExNTJ3IN88US=>	NVHWbIpKOTZiaB?=	M1;wS2lvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{NkSxNEc,OjJyMk[0NVA9N2F-
human HCT116 cells	M1vmfmZ2dmO2aX;uJIF{e2G7	NXLnUFV7OTBizszN		NW\wbYFKUW6qaXLpeIlwdiCxZjDBb5Qh\XiycnXzd4lwdiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZQhOTBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NV\rOIttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells	NVfsfnl1TnWwY4Tpc44h[XO\|YYm=	MWCxNEDPxE1?		MorITY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	NITpOIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells	Mo\2SpVv[3Srb36gZZN{[Xl?	MUKxNEDPxE1?		NW\tfIFbUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	NXj4dGtsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells	NX61NnVjTnWwY4Tpc44h[XO\|YYm=	NUHTeGp2OTBizszN	MkD5NVAhdWmw	MVfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyC3c3nu[{BcOzKSXVHUVEBifCBzMDD1UUBi\nSncjCxNEBucW6\|	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells	MVHGeY5kfGmxbjDhd5NigQ>?	MVWxNEDPxE1?	NXfHXmZZOTBibXnu	NUfENldqUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KHW\|aX7nJHs{OlCfQWTQJIF1KDFyIIXNJIFnfGW{IEGwJI1qdnN?	NFTiUZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MonNOFghcA>?	NE\1RnFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNib4\ldoV5eHKnc4PpcochWEl\|S3HsdIhiKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9Ok44KM7:TT6=	NXLjU5Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells	M3jxXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4PERVQ5KGh?	MYLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlgh\|ryPLh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells	MlfsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4TqNVQ5KGh?	MkXQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5\|IN88US=>	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO\|IyRC:jPh?=
human A549 cells	M3rYRmN6fG:2b4jpZ:Kh[XO\|YYm=		NV6ySVhlPzJiaB?=	M2C0eGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfS=>	NFv4WIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
human PC3 cells	M{nWNmN6fG:2b4jpZ:Kh[XO\|YYm=		MWm3NkBp	M3TWSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPU[xMlM2KM7:TT6=	NF\JZWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
human HL60 cells	NGLOPZJEgXSxdH;4bYPDqGG\|c3H5		MVG3NkBp	NVHXW2VbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvQTRizszNMi=>	NGrGV409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
Sf21 cells	NXfBepJnTnWwY4Tpc44h[XO\|YYm=			NWS0PXRtUW6qaXLpeIlwdiCxZjDtc5V{\SC5aXzkJJR6eGViUFmzT4FteGijIHX4dJJme3OnZDDpckBU\jJzIHPlcIx{KGOxLXX4dJJme3OrbnegUk11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJA5PWFidYPpcochVC2jbIDoZU1xcG:\|cHjheIllgWyrbn;zbZRwdCC\|dXLzeJJifGViYomgWGxEKGKjc3XkJJBpd3OyaH;yJIlu[WerbnesJGlEPTB;MD61JO69VQ>?	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MkC2N\|AoRjJ{NUKwOlMxRC:jPh?=
HEK293 cells	M4rsdmZ2dmO2aX;uJIF{e2G7		NXfIPWRbOS53IHi=	M4TvWWRqe3CuYXPlcYVvfCCxZjDbN2heVFOGIH\yc40hcHWvYX6gOWhVPiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGGodHXyJFEvPSCqcoOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmd?	NIDhS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzO\|E2Oyd-MkK1N\|cyPTN:L3G+
human H1299 cells	M2ixeWZ2dmO2aX;uJIF{e2G7	MYiwMlEuOzBizszN	NFTUfoczPCCq	M{C4UWlv\HWldHnvckBw\iCMTlutcYVlcWG2ZXSgR2hQWCCneIDy[ZN{cW:wIHnuJIh2dWGwIFixNlk6KGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M2H2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
human H1299 cells	M{H0N2Z2dmO2aX;uJIF{e2G7	NWfvTVA{OC5zLUOwJO69VQ>?	NVLyZVNwOjRiaB?=	MnLmTY5lfWO2aX;uJI9nKESUNTDlfJBz\XO\|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB\|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells	M{izO2Z2dmO2aX;uJIF{e2G7	MWSwMlEuOzBizszN	MYWyOEBp	MWrEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{	M2LwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
human H1299 cells	M4XWNmZ2dmO2aX;uJIF{e2G7	M1;WXVAvOS1\|MDFOwG0>	NF6yNGYzPCCq	MXnEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
MDA-MB-231 cells	NV\2ZY5jS2WubDDpcpZie2mxbjDhd5NigQ>?		NXW3e\|h4OjRiaB?=	MWTJcohq[mm2aX;uJI9nKGWyaYTo[Yxq[WxiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIH;mJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNicILlMYlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHPlcIwhcW64YYPpc44h[XO\|YYmsJGlEPTB;MD6zPEDPxE1w	NVPY[YVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFQyODhpPkKyPFA1OTB6PD;hQi=>
human LNCAP cells	NUDNfYhUTnWwY4Tpc44h[XO\|YYm=	MWewMlEuOzBizszN	NWfETIRxOjRiaB?=	M3vnO2Rwf26{ZXf1cIF1cW:wIH;mJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M2mxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN\|E3Lz5{MkizNlMyPjxxYU6=
human LNCAP cells	MVnGeY5kfGmxbjDhd5NigQ>?	MY[wMlEuOzBizszN	MUWzNEBucW5?	MmPyTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB\|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|MkOxOkc,OjJ6M{KzNVY9N2F-
human PC3 cells	M4TMSGZ2dmO2aX;uJIF{e2G7	M4rUSVUxKM7:TR?=	M1\zblghcA>?	M{\0OGlv\HWldHnvckBw\iCyMkGgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBEOyClZXzsd{BifCB3MDD1UUBqdmO3YnH0[YQh\m:{IEigbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdicnXsZZRqfmVidH:geY51emWjdHXkJINwdnS{b3y=	NX\XfoJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PVg1PzJpPkKyPVk5PDd{PD;hQi=>
human BT474 cell	NVj1dZRwWHKxbHnm[ZJifGmxbjDhd5NigQ>?		MYq3NkBp	NWfHR\|dUUW6qaXLpeIlwdiCxZjDoeY1idiCEVES3OEBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd-+9lCCLQ{WwQVIxNjdizszNMi=>	NInsWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cell	NImwOWJRem:uaX\ldoF1cW:wIHHzd4F6		MXq3NkBp	MUHJcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4>	M1jFZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGwNFA2Lz5{M{SxNFAxPTxxYU6=
human PC3 cells	M1S5TmZ2dmO2aX;uJIF{e2G7		MXKzNEBucW5?	NGnMTXNKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRic3XybY5mKDR5MzDh[pRmeiB\|MDDtbY5{KGK7IFXMTXNCNCCLQ{WwQVEvO87:TT6=	NV\teo12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVAxODVpPkKzOFExODB3PD;hQi=>
human MGC803 cells	Ml63SpVv[3Srb36gZZN{[Xl?	NGjDeY8zPSEQvF2=	NU\lWFdPPDhiaB?=	MlzYR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWdEQDB\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFI2KHWPIHHmeIVzKDR6IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTldkBz\WyjdHn2[UB1dyClb370do9t	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzOUi2PUc,OjRzMUm4Olk9N2F-
mouse RAW264.7 cells	Moq5SpVv[3Srb36gZZN{[Xl?	MlzxNlUh\|ryP	NFvBZlIzOCCq	MmTOTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO\|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M3zrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm5OlE3Lz5{NEK5PVYyPjxxYU6=
human A549 cells	MWrQdo9tcW[ncnH0bY9vKGG\|c3H5		NGn0UYg4OiCq	NIDNdndCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;OEKuN\|Ih\|ryPLh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HuH7 cells	NX3ReWsyWHKxbHnm[ZJifGmxbjDhd5NigQ>?		MWq3NkBp	NYfB[oVPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPU[3MlE5KM7:TT6=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HCT116 cells	NH\POYdRem:uaX\ldoF1cW:wIHHzd4F6		MoX2O\|IhcA>?	Mly4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NUGuPFIh\|ryPLh?=	NFLzToc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N\|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells	NE\aWFVRem:uaX\ldoF1cW:wIHHzd4F6		NFvobok4OiCq	MlXIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTF6LkSzJO69VS5?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
Sf9 cells	MnLFSpVv[3Srb36gZZN{[Xl?			MU\Jcohq[mm2aX;uJI9nKEircz30ZYdo\WRiaIXtZY4hS0t{IHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUCgQUA3NjlizszNMi=>	MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUizOVEoRjFyOUm4N\|UyRC:jPh?=
HeLa cells	NF7abmVHfW6ldHnvckBie3OjeR?=			NVXRZoZbUW5idnn0do8hcW6qaXLpeIlwdiCxZjDEUmEu\GWyZX7k[Y51KHC{b4TlbY4hc2mwYYPlLGRPSS2SSzmg[pJwdSCKZVzhJEhpfW2jbjDjZZJkcW6xbXGpJINmdGy\|LjygTWM2OCB;IEGuOEDPxE1w	NWHsZmg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK5OFE{OzlpPkGyPVQyOzN7PD;hQi=>
HeLa cells	NITFPVNHfW6ldHnvckBie3OjeR?=			MUTJcohq[mm2aX;uJI9nKESQQTDk[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCLQ{WwJF0hOS53IN88UU4>	M2D4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
Sf21 cells	NHXEXFFHfW6ldHnvckBie3OjeR?=			NWn1bGZ{UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[mW2YTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OCB;IECuPUDPxE1w	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf21 cells	MoXCSpVv[3Srb36gZZN{[Xl?			NWnoWJBiUW6qaXLpeIlwdiCxZjDic5ZqdmVicnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lIyKGOnbHzzMEBKSzVyIE2gO{DPxE1w	MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEiyOlkoRjF7N{S4NlY6RC:jPh?=
HeLa cells	NVrTNVVKTnWwY4Tpc44h[XO\|YYm=			M{LrW2FkfGm4aYT5JIF1KFCLM1ugbY4hcHWvYX6gTIVN[SClZXzsd{BjgSCHTFnTRUwhTUN3MDC9JFEvPSEQvF2u	M332S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEmyN\|I{Lz5{MEC5NlMzOzxxYU6=
Sf21 cells	NHjZTGRHfW6ldHnvckBie3OjeR?=			M17CXWlvcGmkaYTpc44hd2ZiUFmzT4RmdHSjIHX4dJJme3OnZDDpckBk\WyuczDjc{1mgHC{ZYPzbY5oKE5vdHXycYlv[WxiSHnzMZRi\2enZDDoeY1idiCyOEXhJJV{cW6pIFytZYxxcGFvcHjvd5Bp[XSrZInsbY5we2m2b3ygd5Vje3S{YYTlJIJ6KFSOQzDiZZNm\CCyaH;zdIhweiCrbXHnbY5oNCCLQ{WwJF0hOC53NzFOwG0v	NUfpS4F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
Sf21 cells	MXzGeY5kfGmxbjDhd5NigQ>?			M{\vNGlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzJINwNWW6cILld5NqdmdiTj30[ZJucW6jbDDIbZMufGGpZ3XkJIh2dWGwIIC4OYEhfXOrbnegUE1idHCqYT3wbI9{eGijdHnkfYxqdm:\|aYTvcEB{fWK\|dILheIUh[nliVFzDJIJie2WmIIDoc5NxcG:{IHntZYdqdmduIFnDOVAhRSByLkm3JO69VS5?	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MkC2N\|AoRjJ{NUKwOlMxRC:jPh?=
HL60 cells	M1PNV2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MW[zJIRigXN?	MoX3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzNDFOwG0v	NHjndFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U937 cells	NXu1PFJOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYq2WYVGOyCmYYnz	NIfKNHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEG0JO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
Jurkat cells	NGOyWpZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4W4ZlMh\GG7cx?=	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDt[YF{fXKnZDDh[pRmeiB\|IHThfZMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMkKg{txONg>?	Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NEWxNVAoRjJ4OUS1NVExRC:jPh?=
K562 cells	NYLabG5qSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHLG[nQ{KGSjeYO=	NVLEdI1QSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCzPEDPxE1w	NIG2eI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MY[zJIRigXN?	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV{Nk[gZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDR4IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
MDA-MB-231 cells	NX64[nFnSW62aX3p[5JifG:{eTDhd5NigQ>?		NEXzRlgzPCCqcoO=	MluzRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEWJRjDpcoR2[2WmIHPo[Y1wfGG6aYOgbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTDFS2Yh[WSmaYTpc44h\m:{IEOuOUBpenNiYomgcIlocHRibXnjdo9{[2:yeTygTWM2OCB;IECuN\|gh\|ryPLh?=	M4nNUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUm4NlM4Lz5{N{W5PFI{PzxxYU6=
MDA-MB-231 cells	MkXMRY51cWmwdnHzbZZmKGG\|c3H5		MX2zMlUhcHK\|	Mn2wRY51cWmwdnHzbZZmKGGldHn2bZR6KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGT0ZvaX7keYNm\CClZXzsJIlvfmG\|aX;uJIFnfGW{IEOuOUBpenNuIFnDOVAhRSByLkO4JO69VS5?	MmL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMEm1NlEoRjJ6MEC5OVIyRC:jPh?=
HEK293T cells	NVHzWodnTnWwY4Tpc44h[XO\|YYm=		NE[4bGsyKGi{	MXjJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u	M4DuTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
HEK293T cells	MmPYSpVv[3Srb36gZZN{[Xl?		MlPMNUBpeg>?	NHLROGJKdmirYnn0bY9vKG:oIHntcY9jcWyrenXkJG4uVFl{OUSwNFIh[mWjZDDibY5lcW6pIITvJHBKO0umZXz0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDFwNUOg{txONg>?	M17Mb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
HEK293T cells	MX\GeY5kfGmxbjDhd5NigQ>?		NGDVc4UyKGi{	NVLHcXVrUW6qaXLpeIlwdiCxZjDpcY1w[mmuaYrl[EBPNUy\Mkm0NFAzKGKnYXSgZolv\GmwZzD0c{BRUTONYXzwbIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{BqdmO3YnH0[YQh\m:{IEGgbJIh[nliTFOtUXMwVVNiYX7hcJl{cXNuIFnDOVAhRSB{LkO3JO69VS5?	NV76PZY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
MDA-MB-231 cells	NGLVbIhHfW6ldHnvckBie3OjeR?=			NHj3Z4dKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJIlvfmG\|aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5\|ODFOwG0v	M37GRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{CyOFAyLz5{OEOwNlQxOTxxYU6=
MCF7 cells	NXn6bY5kTnWwY4Tpc44h[XO\|YYm=	MoHnNVAhfU1?	NILuWYgyKGi{	MmDPTY5pcWKrdHnvckBw\iCLR1[xVkBxcG:\|cHjvdplt[XSrb36gZZQhXHm{MUG2NUBz\XOrZIXlJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNUBpeiCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIludXWwb3jpd5Rw[2inbXnjZYwh[W6jbInzbZM>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N\|A9N2F-
SKOV3 cells	MXHGeY5kfGmxbjDhd5NigQ>?	MWWyNEB2VQ>?	MYOyOEBpenN?	M4TxcGlvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJIlvfmG\|aX;uJIlvKGi3bXHuJHNMV1Z\|IHPlcIx{KGG2IEKwJJVOKGGodHXyJFI1KGi{czDpckBjgSCvYYTybYdmdCCrbo\hd4lwdiCjc4PhfS=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF{MkS4OEc,OjlzMkK0PFQ9N2F-
SKOV3 cells	M3vYOWFvfGmvaXfyZZRwenliYYPzZZk>	MlzRNlAhfU1?	M3T0OlI1KGi{cx?=	M{Cx[WFvfGmvaXfyZZRwenliYXP0bZZqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEKGTl[tbY5lfWOnZDDj[YxtKG2rZ4LheIlwdiCjdDCyNEB2VSCjZoTldkAzPCCqcoOgZpkhe2O{YYTjbEB4d3WwZDDo[YFtcW6pIHHzd4F6	NWP0[G1sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNlI1QDRpPkK5NVIzPDh2PD;hQi=>
NB1643 cells	M2TVRpFJXFNiYYPzZZk>			Mn\JdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NXT1SHdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 cells	M1LxNZFJXFNiYYPzZZk>			NIfLdoNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 cells	NHLMclNyUFSVIHHzd4F6			MnHndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NF;DN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC cells	NVjGSoN4eUiWUzDhd5NigQ>?			MnzrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
J774 cells	Mke5RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		NVm0NllNOjRiaILz	MYfBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIFq3O\|Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFzQV{1qdmS3Y3XkJG1EWDFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUA{NjdizszNMi=>	M3jVTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells	NYe1dVM{SW62aXnu[oxidW2jdH;yfUBie3OjeR?=		NEf3fpMzPCCqcoO=	Mn74RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W\|ZTDKO\|c1KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBKVDZiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUA2NjFizszNMi=>	NEm0dGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+
J774 cells	MYjBcpRqcW6obHHtcYF1d3K7IHHzd4F6		NGfFc3EzPCCqcoO=	MYnBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIFq3O\|Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHHmeIVzKDJ2IHjyd{BjgSCJcnnld5Mh[XO\|YYmsJGlEPTBiPTC4Mlkh\|ryPLh?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells	Mnq3SpVv[3Srb36gZZN{[Xl?	NXLu[Ys{OTBidV2=	MVO0JIhzew>?	M2DqN2lvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gcY92e2ViSke3OEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iTGDTMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYK0O\|Mh[XRiMUCgeW0h[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NGr3d\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473	29731993 25344912 23251002 20649566
Growth inhibition assay	Cell viability	25344912
Immunofluorescence	α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a	27671604 29731993 18388194
ELISA	IL-10 / IL-1β / TNFα / IL-6	22208359

In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. ^[2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. ^[3]

Protocol (from reference)

Kinase Assay: ^[4]	kinase assays: PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24^oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research: ^[2]	Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205 Concentrations: 0–50 μM Incubation Time: 0–48 hours Method: 1.0×10⁵ cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37^oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37^oC, after which absorbance at 450 nm is measured with a microplate reader. (Only for Reference)
Animal Research: ^[3]	Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells Dosages: 0–100 mg/kg Administration: Administered via i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	36 mg/mL warmed (117.13 mM)
	Water	Insoluble
	Ethanol	'21 mg/mL
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	307.34
Formula	C₁₉H₁₇NO₃
CAS No.	154447-36-6
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

Download LY294002 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02337309	Terminated	Drug: SF1126	Neuroblastoma	New Approaches to Neuroblastoma Therapy Consortium\|SignalRX Pharmaceuticals Inc.\|University of Southern California	July 9 2015	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):